BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells

  • Liu, Zhi (Department of Respiratory Medicine, The First Hospital of Jilin University) ;
  • Xu, Lijun (Department of Respiratory Medicine, The First Hospital of Jilin University)
  • Received : 2018.07.04
  • Accepted : 2018.10.23
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Ubiquitin-conjugating enzyme E2S (UBE2S), a family of E2 protein in the ubiquitination process, is involved in development of various cancers. However, its role in lung adenocarcinoma, has not been well elucidated. In this report, we attempted to investigate expression and function of UBE2S in lung adenocarcinoma. Up-regulation of UBE2S at mRNA, and protein level, was observed in human cancer tissues and lung adenocarcinoma cells. Higher UBE2S expression correlated with poorer prognosis of lung adenocarcinoma patients. UBE2S expression was efficiently suppressed by lentivirus-mediated shRNA strategy in A549 cells, and UBE2S silencing led to reduced cell proliferation, colony formation, and enhanced apoptosis. Inverse results were observed, in UBE2S over-expressed H1299 cells. Microarray analysis indicated that a large number of genes were regulated by UBE2S, and p53 signaling pathway may be critical, to the role of UBE2S in cancer development. Together, UBE2S could be a potential target for lung adenocarcinoma.

Keywords

References

  1. Jemal A, Thomas A, Murray T and Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52, 23-47 https://doi.org/10.3322/canjclin.52.1.23
  2. Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 https://doi.org/10.1016/j.cell.2012.08.029
  3. McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7, 418-419 https://doi.org/10.3945/an.116.012211
  4. Alberg AJ, Brock MV, Ford JG, Samet JM and Spivack SD (2013) Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e1S-e29S https://doi.org/10.1378/chest.12-2345
  5. Paul A and Wang B (2017) RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage. Mol Cell 66, 458-472.e455 https://doi.org/10.1016/j.molcel.2017.04.013
  6. Wu T, Merbl Y, Huo Y, Gallop JL, Tzur A and Kirschner MW (2010) UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex. Proc Natl Acad Sci U S A 107, 1355-1360 https://doi.org/10.1073/pnas.0912802107
  7. Garnett MJ, Mansfeld J, Godwin C et al (2009) UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit. Nat Cell Biol 11, 1363-1369 https://doi.org/10.1038/ncb1983
  8. Bremm A, Freund SM and Komander D (2010) Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat Struct Mol Biol 17, 939-947 https://doi.org/10.1038/nsmb.1873
  9. Penas C, Ramachandran V and Ayad NG (2011) The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol 1, 60
  10. Chen MF, Lee KD, Lu MS et al (2009) The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med (Berl) 87, 307-320 https://doi.org/10.1007/s00109-008-0430-3
  11. Roos FC, Evans AJ, Brenner W et al (2011) Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma. Am J Pathol 178, 853-860 https://doi.org/10.1016/j.ajpath.2010.10.033
  12. Liang J, Nishi H, Bian ML et al (2012) The ubiquitinconjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth. Oncol Rep 28, 1519-1525 https://doi.org/10.3892/or.2012.1949
  13. Ayesha AK, Hyodo T, Asano E et al (2016) UBE2S is associated with malignant characteristics of breast cancer cells. Tumour Biol 37, 763-772 https://doi.org/10.1007/s13277-015-3863-7
  14. Jung CR, Hwang KS, Yoo J et al (2006) E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12, 809-816 https://doi.org/10.1038/nm1440
  15. Li Z, Wang Y, Li Y et al (2018) Ube2s stabilizes beta-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis 9, 456 https://doi.org/10.1038/s41419-018-0451-y
  16. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388 https://doi.org/10.1056/NEJMoa0909530
  17. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239-246 https://doi.org/10.1016/S1470-2045(11)70393-X
  18. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 12, 735-742 https://doi.org/10.1016/S1470-2045(11)70184-X
  19. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121-128 https://doi.org/10.1016/S1470-2045(09)70364-X
  20. Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31, 3327-3334 https://doi.org/10.1200/JCO.2012.44.2806
  21. Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15, 213-222 https://doi.org/10.1016/S1470-2045(13)70604-1
  22. Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371, 2167-2177 https://doi.org/10.1056/NEJMoa1408440
  23. Dimova NV, Hathaway NA, Lee BH et al (2012) APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1. Nat Cell Biol 14, 168-176 https://doi.org/10.1038/ncb2425
  24. Kirkpatrick DS, Hathaway NA, Hanna J et al (2006) Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat Cell Biol 8, 700-710 https://doi.org/10.1038/ncb1436
  25. Peters JM (2002) The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9, 931-943 https://doi.org/10.1016/S1097-2765(02)00540-3
  26. Ben-Eliezer I, Pomerantz Y, Galiani D, Nevo N and Dekel N (2015) Appropriate expression of Ube2C and Ube2S controls the progression of the first meiotic division. FASEB J 29, 4670-4681 https://doi.org/10.1096/fj.15-274522
  27. Pan YH, Yang M, Liu LP, Wu DC, Li MY and Su SG (2018) UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun 503, 895-902 https://doi.org/10.1016/j.bbrc.2018.06.093
  28. Lin TH, Hsu WH, Tsai PH et al (2017) Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling. Food Funct 8, 1558-1568 https://doi.org/10.1039/C6FO00551A
  29. Yoshimura S, Kasamatsu A, Nakashima D et al (2017) UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system. Biochem Biophys Res Commun 485, 820-825 https://doi.org/10.1016/j.bbrc.2017.02.138
  30. Yang Y, Guo J, Hao Y et al (2017) Silencing of karyopherin alpha2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget 8, 36289-36304